Zuclopenthixol dihydrochloride | CAS#58045-23-1

MedKoo Cat#: 526500 | Name: Zuclopenthixol dihydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zuclopenthixol, also known as Cisordinol, Clopixol, Acuphase, zuclopentixol, is a typical antipsychotic drug of the thioxanthene class. It was introduced in 1962 by Lundbeck. Zuclopenthixol is the cis-isomer of clopenthixol. Zuclopenthixol is not approved for use in the United States. Zuclopenthixol has high affinity for both dopamine D1 and D2 receptors, for α1-adrenoceptors and 5-HT2 receptors but no affinity for cholinergic muscarine receptors. It has weak histamine (H1) receptor affinity and no α2-adrenoceptor blocking activity.

Chemical Structure

Zuclopenthixol dihydrochloride

CAS#58045-23-1 (HCl)

Theoretical Analysis

MedKoo Cat#: 526500

Name: Zuclopenthixol dihydrochloride

CAS#: 58045-23-1 (HCl)

Chemical Formula: C22H27Cl3N2OS

Exact Mass: 472.0900

Molecular Weight: 473.88

Elemental Analysis: C, 55.76; H, 5.74; Cl, 22.44; N, 5.91; O, 3.38; S, 6.77

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

53772-83-1 (free base) 58045-23-1 (HCl) 85721-05-7 (acetate) 64053-00-5 (decanoate)

Synonym

Zuclopenthixol dihydrochloride; Zuclopenthixol HCl; alpha-Clopenthixol; Cisordinol; Clopenthixol; Zuclopenthixol; Cisordinol; cis-Clopenthixol; Clopixol;

IUPAC/Chemical Name

2-[4-[(3Z)-3-(2-Chlorothioxanthen-9-ylidene)propyl]piperazin-1-yl]ethanol dihydrochloride

InChi Key

LPWNZMIBFHMYMX-MHKBYHAFSA-N

InChi Code

InChI=1S/C22H25ClN2OS.2ClH/c23-17-7-8-22-20(16-17)18(19-4-1-2-6-21(19)27-22)5-3-9-24-10-12-25(13-11-24)14-15-26;;/h1-2,4-8,16,26H,3,9-15H2;2*1H/b18-5-;;

SMILES Code

ClC1=CC(/C2=C\CCN3CCN(CCO)CC3)=C(SC4=C2C=CC=C4)C=C1.[H]Cl.[H]Cl

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 473.88 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

This message contains search results from the National Center for Biotechnology Information (NCBI) at the U.S. National Library of Medicine (NLM). Do not reply directly to this message Sent On: Mon Oct 19 09:29:06 2020 Search: Zuclopenthixol [title] 20 selected items PubMed Results Items 1-20 of 20 (Display the 20 citations in PubMed) 1: Tveito M, Smith RL, Molden E, Høiseth G. Impact of age and CYP2D6 genotype on exposure of zuclopenthixol in patients using long-acting injectable versus oral formulation-an observational study including 2044 patients. Eur J Clin Pharmacol. 2020 Sep 30. doi: 10.1007/s00228-020-03002-y. Epub ahead of print. PMID: 33000414. 2: Herath U, Thomas N, Krishna A, Pantelis C. Electroencephalography identifies encephalopathy associated with adjunctive lithium and zuclopenthixol. Aust N Z J Psychiatry. 2019 Aug;53(8):814-815. doi: 10.1177/0004867418823277. Epub 2019 Jan 17. PMID: 30654623. 3: Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006–. Zuclopenthixol. 2018 Dec 3. PMID: 30000827. 4: Bryan EJ, Purcell MA, Kumar A. Zuclopenthixol dihydrochloride for schizophrenia. Cochrane Database Syst Rev. 2017 Nov 16;11(11):CD005474. doi: 10.1002/14651858.CD005474.pub2. PMID: 29144549; PMCID: PMC6486001. 5: Allibe N, Kintz P, Faure A, Paysant F, Michard-Lenoir AP, Stanke-Labesque F, Scolan V, Eysseric-Guerin H. Interest of Single Hair Analysis to Document Drug Exposure: Literature Review and a Case Report Involving Zuclopenthixol. Curr Pharm Des. 2017;23(36):5502-5510. doi: 10.2174/1381612823666170622100443. PMID: 28641534. 6: Tibrewal P, Bastiampillai T, Dhillon R, Cheng R, Fonseka HT. Use of zuclopenthixol in the treatment of aggression in Huntington's disease. Asian J Psychiatr. 2017 Apr;26:152-153. doi: 10.1016/j.ajp.2017.01.011. Epub 2017 Jan 19. PMID: 28483083. 7: Patteet L, Haufroid V, Maudens K, Sabbe B, Morrens M, Neels H. Erratum to: Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2017 Jan;73(1):127. doi: 10.1007/s00228-016-2144-8. Erratum for: Eur J Clin Pharmacol. 2016 Feb;72 (2):175-84. PMID: 27738718. 8: Laubscher LL, Hoffman LC, Pitts NI, Raath JP. THE EFFECT OF A SLOW-RELEASE FORMULATION OF ZUCLOPENTHIXOL ACETATE (ACUNIL®) ON CAPTIVE BLUE WILDEBEEST (CONNOCHAETES TAURINUS) BEHAVIOR AND PHYSIOLOGICAL RESPONSE. J Zoo Wildl Med. 2016 Jun;47(2):514-22. doi: 10.1638/2015-0099.1. PMID: 27468024. 9: Cordiner M, Shajahan P, McAvoy S, Bashir M, Taylor M. Effectiveness of long- acting antipsychotics in clinical practice: 2. Effects of antipsychotic polypharmacy on risperidone long-acting injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol. 2016 Apr;6(2):66-76. doi: 10.1177/2045125315623584. Epub 2016 Jan 6. PMID: 27141289; PMCID: PMC4837966. 10: Cordiner M, Shajahan P, McAvoy S, Bashir M, Taylor M. Effectiveness of long- acting antipsychotics in clinical practice : 1. A retrospective, 18-month follow up and comparison between paliperidone palmitate, risperidone long-acting injection and zuclopenthixol decanoate. Ther Adv Psychopharmacol. 2016 Feb;6(1):22-32. doi: 10.1177/2045125315623168. PMID: 26913175; PMCID: PMC4749742. 11: Lacey M, Jayaram MB. Zuclopenthixol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2015 Dec 1;(12):CD010598. doi: 10.1002/14651858.CD010598.pub2. PMID: 26624987. 12: Lisbeth P, Vincent H, Kristof M, Bernard S, Manuel M, Hugo N. Genotype and co-medication dependent CYP2D6 metabolic activity: effects on serum concentrations of aripiprazole, haloperidol, risperidone, paliperidone and zuclopenthixol. Eur J Clin Pharmacol. 2016 Feb;72(2):175-84. doi: 10.1007/s00228-015-1965-1. Epub 2015 Oct 30. Erratum in: Eur J Clin Pharmacol. 2016 Oct 13;: PMID: 26514968. 13: Hässler F, Dück A, Jung M, Reis O. Treatment of aggressive behavior problems in boys with intellectual disabilities using zuclopenthixol. J Child Adolesc Psychopharmacol. 2014 Dec;24(10):579-81. doi: 10.1089/cap.2014.0066. PMID: 25514543. 14: Wichowicz HM, Wilkowska A, Banecka-Majkutewicz Z, Kummer Ł, Konarzewska J, Raczak A. Mineralizacja jader podstawy jako domniemana przyczyna złej tolerancji zuklopentyksolu u chorej z wieloletnia nieleczona schizofrenia paranoidalna [Mineralization of the basal ganglia as the supposed cause of poor tolerance of zuclopenthixol in a patient with long-term untreated paranoid schizophrenia]. Psychiatr Pol. 2013 Jul-Aug;47(4):599-607. Polish. PMID: 24946467. 15: Lertxundi U, Hernandez R, Albeniz JM, Echaburu SD, Ruiz B, García MG, Aguirre C. Possible interaction between letrozole and long-acting injectable zuclopenthixol. Nord J Psychiatry. 2015 Jan;69(1):79-80. doi: 10.3109/08039488.2014.915341. Epub 2014 May 16. PMID: 24831298. 16: Schwarz V, Reis O, Glaser T, Thome J, Hiemke C, Haessler F. Therapeutic drug monitoring of zuclopenthixol in a double-blind placebo-controlled discontinuation study in adults with intellectual disabilities and aggressive behaviour. Pharmacopsychiatry. 2014 Jan;47(1):29-32. doi: 10.1055/s-0033-1361115. Epub 2013 Dec 4. PMID: 24307207. 17: Rej S, Desautels R. Experience with intramuscular zuclopenthixol and medroxyprogesterone acetate in the treatment of agitation and aggression in Huntington's disease. J Neuropsychiatry Clin Neurosci. 2013 Summer;25(3):E33-4. doi: 10.1176/appi.neuropsych.12070164. PMID: 24026736. 18: Adami C, Wenker C, Hoby S, Morath U, Bergadano A. Anaesthesia with medetomidine-ketamine-isoflurane with and without midazolam, in eight captive chimpanzees (Pan troglodytes) premedicated with oral zuclopenthixol. Schweiz Arch Tierheilkd. 2013 Aug;155(8):471-6. doi: 10.1024/0036-7281/a000493. PMID: 23919974. 19: Janjić V, Milovanović DR, Zecević DR, Loncar D, Laban O, Stepanović M, Varjaric M, Obradović S, Dejanović SD, Janković S. Zuclopenthixol decanoate in pregnancy: successful outcomes in two consecutive offsprings of the same mother. Vojnosanit Pregl. 2013 May;70(5):526-9. doi: 10.2298/vsp120208005j. PMID: 23789295. 20: Menager C, Boimond N, Cheron G. Intoxication au zuclopenthicol benzoate : mise en évidence par chromatographie [Zuclopenthixol benzoate poisoning in a child: evidence from chromatography]. Arch Pediatr. 2013 Mar;20(3):286-8. French. doi: 10.1016/j.arcped.2012.12.009. Epub 2013 Feb 8. PMID: 23465463.